Valneva SE announced that an End Of Phase 2 (EOP2) meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on February 24, 2020 for its single-shot chikungunya vaccine candidate, VLA1553. The Company plans to present its plan for Phase 3 clinical studies and licensure. VLA1553 has been awarded Fast Track designation by the FDA and may be eligible for a Priority Review Voucher. In November 2019, Valneva reported final Phase 1 results confirming VLA1553’s excellent immunogenicity and safety profile. The Company has also completed all required non-clinical studies requested by the FDA.